comprehensive -WSS

comprehensive

author：entertainment 2025-09-30 00:51:49 - browse：731

A man enters the Regeneron Clinic at a monoclonal antibody treatment site in Pembroke Pines, Florida – politics and policy coverage from STAT — Regeneron agreed to price limits for a new Covid-19 drug that will be developed in partnership with the Department of Health and Human Services. CHANDAN KHANNA/AFP via Getty Images

WASHINGTON — A groundbreaking clause in a new deal between the Department of Health and Human Services and the pharmaceutical company Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers’ list prices, experts told STAT.

The contract between Regeneron and the government requires that the list price for a future monoclonal antibody drug to prevent Covid-19 is the same or lower in the United States as in other high-income countries. The release doesn’t explain which countries the government will be comparing prices with, or how pricing data will be determined.

The deal was part of the White House’s Project NextGen initiative, which includes $5 billion in new vaccines and therapies. HHS announced that it is spending $326 million to help Regeneron develop a new monoclonal antibody to prevent Covid-19. Regeneron in January announced plans to start testing a potentially variant-proof antibody, which is set to go into clinical trials later this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Biotech venture capitalists face new demands from investors

WSS

5 dead in mass shooting on Caribbean island of St. Vincent: Police

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Scientists grapple with ethics of stem cell research

When a patient nears the end, a feared therapy can comfort

explore

comprehensive

leisure time

Cancer drug shortages should be causing more outrage

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Delta passengers in Vegas fall sick while waiting on flight in triple

After affirmative action ruling, medical educators look to 'holistic review'

My yearlong odyssey to get my son’s ADHD medication covered

Moonlake's readout produced a cash windfall. Risks remain

Prior authorization will have to move faster under new Biden rule

ChatGPT in medicine: STAT answers readers' burning questions

After a decade, new Gardasil ad campaign gets it (mostly) right

leisure time

Independent physicians launch a new lobbying group

A new ‘biological computer' targets cancer while sparing healthy cells

Are infertility treatments 'essential' during the Covid

The tragedy of Johnson & Johnson’s Covid vaccine

When a patient nears the end, a feared therapy can comfort

Judge denies Trump's request for new trial in E. Jean Carroll case

hotspot

explore

leisure time

focus